Short Courses | Day 1 | Day 2 | Download Brochure  

Thursday, May 20


12:00 pm Registration




1:30 Chairperson’s Opening Remarks

1:40 Conferring Meaningful Anti-Tumor Activity to Monoclonal Antibodies by Linking Cell Killing Agents

Ravi V. Chari, Ph.D., Executive Director, Chemistry & Biochemistry, ImmunoGen, Inc.

A majority of antibodies developed against cancer targets display only modest cell killing activity to be therapeutically useful. Linking highly cytotoxic cell killing agents to antibodies to provide Antibody-Drug Conjugates (ADCs) offers a means to enhance the anti-tumor activity of antibodies.  Multiple ADCs that utilize ImmunoGen’s maytansinoid cell killing agents are currently undergoing clinical evaluation and promising results are emerging.  This talk will review ImmunoGen’s approaches to design each ADC to achieve the best performance for the specific cancer target.

2:10 Recombinant Human Multi-Domain Fusion Proteins

Stefan Barth, Ph.D., Department of Pharmaceutical Product Development, Fraunhofer IM

Under pathological conditions, activated and dysregulated macrophages play a decisive role in the development of numerous inflammatory processes including progression of cancer. The high affinity receptor for IgG (CD64) is highly expressed on monocytes and macrophages is a prime target for therapeutic intervention. We have generated novel recombinant multi-domain immunotherapeutics by fusing different cytotoxic enzymes to a single chain fragment derived from the CD64-specific human antibody H22. Final aim is the application of tailor-made immunofusions not only considering the targeting moiety, but also the appropriate cytotoxic agent to specifically destroy diseased cells.

2:40 Design and Produce Better Antibodies with Antigen Profiler Thermo Scientific logo 
Matt Baker, Proteomics Business Development Director, Thermo Fisher Scientific
Antibodies play a key role in many research and preclinal projects and can be a serious limiting factor in the progression of the project when existing commercial antibodies do not perform as needed or no commercial antibodies are available.  Thermo Scientific has combined years of experience in antibody development along with advanced antigen design algorithms and targeted antigen display to overcome many the challenges of generating robust antibodies.  See how antibodies can be designed and optimized to perform in specific applications through better technology.

3:10 Networking Refreshment Break, Poster and Exhibit Viewing

4:00 Optimizing Antibody Homogeneity and Development: Lessons Learned from Structural and Functional Studies

Alain Beck, Ph.D., Head of Department, Physico-Chemistry, Institut de Recherche Pierre Fabre

High-resolution Mass Spectrometry methods in combination with ultra-performance separation techniques are now routinely used at all stages of antibody discovery and development to assess their structure. As a consequence, these new analytical tools result also in the identification of minor components like charge variants, glycoforms, disulfide bridge isoforms and other low level molecular species. Lessons learned from the impact of these micro-variants on the stability and the PK/PD will be discussed and illustrated by the design of the next generation of optimized antibody-leads with higher homogeneity, stability and potency.

4:30 Antibody-Drug Conjugates to Improve Therapeutic Index

Wei Liao, Ph.D., Senior Research Scientist, Project Team Leader, BioTherapeutic Center of Emphasis, Pfizer, Inc.

Antibody-drug conjugates (ADC) are an effective way to reduce toxicity and to enable site-specific drug delivery. In this presentation, we will discuss the strategies used to meet the challenges to generate the conjugates, and to develop analytical methods, including functional bioassays.

5:00 End of Day

Short Courses | Day 1 | Day 2 | Download Brochure

Program Navigation

Phage and Yeast Display of Antibodies and Proteins Engineering Antibodies Antibody Optimization Difficult to Express Proteins Pre-Clinical/Clinical Development Revival of Bispecific Antibodies Immunogenicity of Therapeutic Biologics Protein Aggregation in Biopharmaceutical Products Biotherapeutic Targets

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag